Direct interaction of the N-terminal domain of ribosomal protein S1 with protein S2 in Escherichia coli.

by Konstantin Byrgazov, Salim Manoharadas, Anna C Kaberdina, Oliver Vesper, Isabella Moll
Published 2012-01-01

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells

by Konstantin Byrgazov, Andrej Besse, Marianne Kraus, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, Lenka Besse
Published 2021-07-01

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

by Konstantin Byrgazov, Thomas Lind, Annica J. Rasmusson, Claes Andersson, Ana Slipicevic, Fredrik Lehmann, Joachim Gullbo, Håkan Melhus, Rolf Larsson, Mårten Fryknäs
Published 2021-12-01

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

by Konstantin Byrgazov, Claes Anderson, Benjamin Salzer, Eva Bozsaky, Rolf Larsson, Joachim Gullbo, Manfred Lehner, Fredrik Lehmann, Ana Slipicevic, Leo Kager, Mårten Fryknäs, Sabine Taschner-Mandl
Published 2020-07-01

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

by Mathias Schneeweiss-Gleixner, Konstantin Byrgazov, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Chantal Blanche Lucini, Susanne Herndlhofer, Sandra Preuner, Klara Obrova, Petra Pusic, Nadine Witzeneder, Georg Greiner, Gregor Hoermann, Wolfgang R. Sperr, Thomas Lion, Michael Deininger, Peter Valent, Karoline V. Gleixner
Published 2019-12-01